The FDA required an extension of three months to review Samsung Bioepis' biologics license application for cancer drug SB3, a biosimilar of Roche Holding unit Genentech's Herceptin, or trastuzumab. The agency is expected to give its decision in January.
Review time for Samsung's cancer drug extended by FDA
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.